The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 10, 2015

Filed:

Apr. 15, 2011
Applicants:

Arlette Darfeuille-michaud, La Roche Blanche, FR;

Paul Hofman, Nice, FR;

Nathalie Rolhion, Clermont Ferrand, FR;

Inventors:

Arlette Darfeuille-Michaud, La Roche Blanche, FR;

Paul Hofman, Nice, FR;

Nathalie Rolhion, Clermont Ferrand, FR;

Assignee:

Universite d'Auvergne Clermont I, Clermond Ferrand, FR;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 39/00 (2006.01); A01N 43/04 (2006.01); A61K 38/16 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); C12N 15/113 (2010.01); G01N 33/68 (2006.01); A61K 38/17 (2006.01); A61K 39/40 (2006.01);
U.S. Cl.
CPC ...
A61K 38/164 (2013.01); C07K 16/18 (2013.01); C07K 16/28 (2013.01); C12N 15/1138 (2013.01); G01N 33/6893 (2013.01); A61K 38/17 (2013.01); A61K 38/177 (2013.01); A61K 39/3955 (2013.01); A61K 39/40 (2013.01); A61K 2039/505 (2013.01); C07K 2317/76 (2013.01); C12N 2310/14 (2013.01); G01N 2800/065 (2013.01);
Abstract

An antagonist of the interaction between the Gp96 receptor andAIEC strains, for the prevention or treatment of inflammatory bowel disease. The antagonist is for specifically blocking or reducing the interaction between Gp96 receptor and the outer membrane vesicles (OMVs), typically the outer protein membrane OmpA ofAIEC strains. The inventions provides for pharmaceutical compositions containing such an antagonist, which may be an antibody against gp96 or OmpA, or a gp96 or OmpA polypeptide. It may be combined to an antagonist of the interaction between the CEACAM6 receptor andAIEC strains, such as an anti-CEACAM6 antibody, a CEACAM6 polypeptide, or a mannoside or particle having a mannose unit. The invention also relates to a method for the diagnosis of inflammatory bowel disease, or of the determination of a predisposition of a person to develop inflammatory bowel disease.


Find Patent Forward Citations

Loading…